NN8765-3658: Phase I/II started

Innate said the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) began an open-label, Canadian Phase I/II trial to evaluate 1, 4 or 10 mg/kg IV IPH2201 every other week in 38 patients. The first part will determine the recommended Phase II dose in 18 patients, after which the dose will be evaluated in platinum sensitive or resistant cohorts of 10 patients each. ...